Cite
HARVARD Citation
Liang, B. et al. (2022). Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers. Clinical pharmacology in drug development. 11 (10), pp. 1184-1190. [Online].